Top

Published in:

01-05-2009 | Clinical Trial

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer

Authors: Rupert Bartsch, Brigitte Mlineritsch, Michael Gnant, Thomas Niernberger, Ursula Pluschnig, Richard Greil, Catharina Wenzel, Paul Sevelda, Josef Thaler, Margaretha Rudas, Michael Pober, Christoph C. Zielinski, Guenther G. Steger, on behalf of the Austrian Fulvestrant Registry

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

Background Endocrine therapy is the preferred treatment in oestrogen- and/or progesterone-receptor (ER/PgR) positive breast cancer. Fulvestrant is a pure ER-antagonist. We present results from the Austrian Fulvestrant Registry. Methods Three-hundred and fifty patients were included. Time to progression (TTP) was defined as primary endpoint. A multivariate analysis was performed to identify factors significantly associated with TTP. Results Fulvestrant was administered as first-line therapy in 26%, second-line in 49%, and third-line or beyond in 25%. TTP was median 7 months. We observed a response in 15% of patients and 41% had SD ≥ 6 months. First-line treatment and non-visceral metastases were associated with longer TTP. One case of pulmonary embolism was reported. Grade 3 toxicities consisted of joint pain (1.4%), nausea (1.4%) and hot flashes (0.3%). Conclusions Fulvestrant was effective and well tolerated. TTP was superior to other trials, due to the large proportion of first-line patients. Activity is apparently independent of Her2-status.

O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(3):20–29. doi:10.1634/theoncologist.10-90003-20 PubMedCrossRef

Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618. doi:10.1056/NEJM199811263392207 PubMedCrossRef

Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0 CrossRef

Paridaens R, Dirix L, Lohrisch C et al (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391–1398. doi:10.1093/annonc/mdg362 PubMedCrossRef

Bajetta E, Procopio G, Ferrari L et al (2002) A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 94:299–304. doi:10.1002/cncr.10239 PubMedCrossRef

Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced beast carcinoma. Cancer 92:2247–2258. doi:10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-YPubMedCrossRef

Dutertre M, Smith CL (2000) Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 295:431–437PubMed

Schiff R, Massarweh SA, Shou J et al (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10(1 Pt 2):331–336. doi:10.1158/1078-0432.CCR-031212 CrossRef

Sun M, Paciga JE, Feldman RI et al (2001) Phosphatidylinostol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (Erα) via interaction between Erα and PI3K. Cancer Res 61:5985–5991PubMed

10.

Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431–2442. doi:10.1056/NEJMra023246 PubMedCrossRef

11.

Miller WR, Bartlett JM, Canney P et al (2007) Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res Treat 103:149–160. doi:10.1007/s10549-006-9369-7 PubMedCrossRef

12.

Macedo LF, Sabnis G, Brodie A (2008) Preclinical modeling of endocrine response and resistance. Cancer 112(Suppl 3):679S–688S. doi:10.1002/cncr.23191 CrossRef

13.

Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873PubMed

14.

Fawell SE, White R, Hoare S et al (1990) Inhibition of estrogen receptor-DNA binding by the “pure” anti-estrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87:6883–6888. doi:10.1073/pnas.87.17.6883 PubMedCrossRef

15.

Wakeling AE (2000) Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 7:17–28. doi:10.1677/erc.0.0070017 PubMedCrossRef

16.

Howell A (2006) Is fulvestrant (“faslodex”) just another selective estrogen receptor modulator? Int J Gynecol Cancer 16(Suppl 2):521S–523S. doi:10.1111/j.1525-1438.2006.00686.x CrossRef

17.

Osborne CK, Shou J, Massarweh S et al (2005) Crosstalk between estrogen receptor and growth factor receptor pathways is a cause for endocrine resistance in breast cancer. Clin Cancer Res 11(2 Pt 2):865–870

18.

Normanno N, Di Maio M, De Maio E et al (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721–747. doi:10.1677/erc.1.00857 PubMedCrossRef

19.

Bartsch R, Wenzel C, Altorjai G et al (2007) Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res 13:4435–4439. doi:10.1158/1078-0432.CCR-06-3050 PubMedCrossRef

20.

Robertson JF, Steger GG, Neven P et al (2007) Fulvestrant in the treatment of Her2-positive advanced breast cancer (ABC). J Clin Oncol 25(Suppl 18):47S. doi:10.1200/JCO.2006.09.3146

21.

Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403. doi:10.1200/JCO.2002.10.057 PubMedCrossRef

22.

Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:386–3395. doi:10.1200/JCO.2002.10.058 CrossRef

23.

Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women—a prospective combined analysis of two multicenter trials. Cancer 98:229–238. doi:10.1002/cncr.11468 PubMedCrossRef

24.

Steger GG, Bartsch R, Wenzel C et al (2005) Fulvestrant (“Faslodex”) in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 41:2655–2661PubMedCrossRef

25.

Steger GG, Gips M, Simon SD et al (2005) Fulvestrant (“Faslodex”): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 31(Suppl 2):10S–16S. doi:10.1016/j.ctrv.2005.08.009 CrossRef

26.

Mlineritsch B, Psenak O, Mayer P et al (2007) Fulvestrant („faslodex”) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the Compassionate Use Programme. Breast Cancer Res Treat 106:105–112. doi:10.1007/s10549-006-9482-7 PubMedCrossRef

27.

Chia S, Gradisher W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromtase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664–1670. doi:10.1200/JCO.2007.13.5822 PubMedCrossRef

28.

Neven P, Paridaens R, Pelgrims G et al (2008) Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat 109:59–65. doi:10.1007/s10549-007-9628-2 PubMedCrossRef

29.

Vergote I, Robertson JFR, Kleeberg U et al (2003) Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 79:207–211. doi:10.1023/A:1023983032625 PubMedCrossRef

30.

Howell A (2002) Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat 76(Suppl 1):72S

31.

Perey L, Paridaens R, Hawle H et al (2007) Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 18:64–69. doi:10.1093/annonc/mdl341 PubMedCrossRef

32.

Beslija S, Bonneterre J, Burstein H et al (2007) Second consenus on medical treatment of metastatic breast cancer. Ann Oncol 18:215–225. doi:10.1093/annonc/mdl155 PubMedCrossRef

33.

Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261PubMedCrossRef

34.

Stendhal M, Ryden L, Nordenskjold B et al (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:4614–4618. doi:10.1158/1078-0432.CCR-06-0248 CrossRef

35.

Ellis MJ, Coop A, Singh B et al (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523–6531PubMed

36.

Nicholson RI, McClelland RA, Robertson JF et al (1999) Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6:373–387. doi:10.1677/erc.0.0060373 PubMedCrossRef

37.

Osborne CK, Schiff R, Fuqua SA et al (2001) Estrogen receptor: current understandings of its activation and modulation. Clin Cancer Res 7(Suppl 12):4338S–4342SPubMed

38.

Howell A, Robertson JFR, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605–1613. doi:10.1200/JCO.2004.02.112 PubMedCrossRef

Title: The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer
Authors: Rupert Bartsch
Brigitte Mlineritsch
Michael Gnant
Thomas Niernberger
Ursula Pluschnig
Richard Greil
Catharina Wenzel
Paul Sevelda
Josef Thaler
Margaretha Rudas
Michael Pober
Christoph C. Zielinski
Guenther G. Steger
on behalf of the Austrian Fulvestrant Registry
Publication date: 01-05-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0132-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy

Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?

Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients

Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones

BRCA1 promoter methylation is associated with increased mortality among women with breast cancer

Cost-effective analyses in Breast Cancer Research and Treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer